AU
UK
CA
US
IND
NZ
Last update at 2024-06-26T21:04:05.590268Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Bruker Appoints Laura Francis to its Board of Directors
Fri 21 Feb 25, 01:00 PMMedtech Marvels: 3 Groundbreaking Medical Device Stocks to Watch in 2024
Thu 25 Apr 24, 10:00 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 120.83M | -8.83500M | -65.61900M | -51.04700M | -41.06400M |
| Minority interest | - | - | - | - | - |
| Net income | 216.00M | -9.13600M | -65.69900M | -51.10900M | -41.10200M |
| Selling general administrative | 56.93M | 34.75M | 23.86M | 14.13M | 5.98M |
| Selling and marketing expenses | 162.00M | 111.29M | 51.67M | 30.62M | 17.54M |
| Gross profit | 424.74M | 195.71M | 46.80M | 25.77M | 5.01M |
| Reconciled depreciation | 4.86M | 5.54M | 3.35M | 2.28M | 0.70M |
| Ebit | 124.13M | -0.87100M | -65.66300M | -51.83900M | -40.61100M |
| Ebitda | 122.71M | -7.73900M | -64.40700M | -49.49400M | -39.91100M |
| Depreciation and amortization | -1.42000M | -6.86800M | 1.26M | 2.35M | 0.70M |
| Non operating income net other | - | -6.86800M | 1.26M | - | - |
| Operating income | 124.13M | -0.87100M | -65.66300M | -51.83900M | -41.20000M |
| Other operating expenses | 365.60M | 238.02M | 133.45M | 94.77M | 53.46M |
| Interest expense | 1.89M | 1.10M | 1.21M | 0.94M | 0.40M |
| Tax provision | -95.16800M | 0.30M | 0.08M | 0.06M | 0.04M |
| Interest income | - | - | - | 0.94M | 0.40M |
| Net interest income | -1.88600M | -1.09600M | -1.21200M | -0.94400M | -0.40100M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -95.16800M | 0.30M | 0.08M | 0.06M | 0.04M |
| Total revenue | 489.73M | 237.15M | 67.79M | 42.93M | 12.26M |
| Total operating expenses | 300.60M | 196.58M | 112.46M | 77.61M | 46.21M |
| Cost of revenue | 65.00M | 41.44M | 20.99M | 17.16M | 7.25M |
| Total other income expense net | -3.30600M | -7.96400M | 0.04M | 0.79M | 0.54M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 216.00M | -9.13600M | -65.69900M | -51.10900M | -41.10200M |
| Net income applicable to common shares | 216.00M | -9.13600M | -65.69900M | -51.10900M | -41.10200M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 1566.56M | 646.09M | 345.68M | 272.04M | 231.94M |
| Intangible assets | 92.86M | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 12.57M | 8.29M | 4.51M | 2.40M | 1.90M |
| Total liab | 897.89M | 134.77M | 103.85M | 46.39M | 39.28M |
| Total stockholder equity | 668.68M | 511.32M | 241.83M | 225.65M | 192.65M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 91.70M | 55.38M | 40.87M | 19.94M | 13.78M |
| Common stock | 0.04M | 0.04M | 0.04M | 0.04M | 0.03M |
| Capital stock | 0.04M | 0.04M | 0.04M | 0.04M | 0.03M |
| Retained earnings | 110.47M | -36.81300M | -252.80900M | -243.67300M | -177.97400M |
| Other liab | - | 12.27M | 12.27M | - | - |
| Good will | 39.57M | - | - | - | - |
| Other assets | - | 102.80M | 1.94M | 9.38M | 1.51M |
| Cash | 328.42M | 156.59M | 89.21M | 50.42M | 139.04M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 104.20M | 63.37M | 51.63M | 25.58M | 24.01M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | 442.19M | -96.18200M | -42.02000M | -25.44300M | -116.32700M |
| Short term debt | 3.64M | 1.28M | 7.24M | 4.17M | 7.44M |
| Short long term debt | - | - | 5.50M | 3.30M | 6.67M |
| Short long term debt total | 770.61M | 60.40M | 47.19M | 24.98M | 22.72M |
| Other stockholder equity | 557.88M | 548.96M | 494.81M | 469.28M | 138.62M |
| Property plant equipment | - | 80.52M | 51.86M | 16.36M | 13.73M |
| Total current assets | 1225.26M | 459.26M | 285.90M | 246.30M | 216.70M |
| Long term investments | 1.64M | 3.51M | 5.99M | - | - |
| Net tangible assets | - | 511.32M | 241.83M | 225.65M | 192.65M |
| Short term investments | 662.13M | 147.91M | 111.77M | 151.93M | 56.30M |
| Net receivables | 114.55M | 71.37M | 37.44M | 11.69M | 7.38M |
| Long term debt | 731.86M | 24.20M | 11.63M | 13.32M | 7.15M |
| Inventory | 107.59M | 75.11M | 42.98M | 29.86M | 12.07M |
| Accounts payable | 8.87M | 6.72M | 3.52M | 1.47M | 2.79M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 0.29M | -0.86700M | -0.20200M | 0.00900M | 0.04M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 0.04M | 0.04M | 0.03M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | -252.80900M | -243.67300M | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 8.03M | 5.23M | 1.94M | 1.81M | 1.51M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 341.30M | 186.83M | 59.78M | 25.74M | 15.24M |
| Capital lease obligations | 38.74M | 36.21M | 30.06M | 8.36M | 8.90M |
| Long term debt total | - | - | 11.63M | 13.32M | 7.15M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -62.15000M | 38.85M | -95.95300M | -59.54300M | 1.81M |
| Change to liabilities | 1.95M | 23.51M | 2.62M | 1.27M | 0.36M |
| Total cashflows from investing activities | -62.15000M | 26.42M | -107.47300M | -59.54300M | -0.17400M |
| Net borrowings | 5.97M | 5.97M | 3.27M | -1.66700M | 14.99M |
| Total cash from financing activities | 13.00M | -2.45100M | 90.03M | 208.05M | 29.81M |
| Change to operating activities | 3.15M | 19.43M | 2.45M | 6.58M | 1.81M |
| Net income | 216.00M | -9.13600M | -65.69900M | -51.10900M | -41.10200M |
| Change in cash | 67.43M | 39.00M | -88.62200M | 100.40M | -11.83000M |
| Begin period cash flow | 90.87M | 51.87M | 140.50M | 40.09M | 51.92M |
| End period cash flow | 158.30M | 90.87M | 51.87M | 140.50M | 40.09M |
| Total cash from operating activities | 117.73M | 15.04M | -71.18400M | -48.10700M | -41.46500M |
| Issuance of capital stock | 0.00000M | 0.00000M | 83.37M | 207.40M | 14.92M |
| Depreciation | 4.86M | 5.54M | 3.35M | 2.28M | 0.70M |
| Other cashflows from investing activities | - | - | - | -55.72600M | 1.81M |
| Dividends paid | - | - | -1.79500M | - | - |
| Change to inventory | -29.71100M | -12.07300M | -17.05600M | -6.82400M | -2.60800M |
| Change to account receivables | -33.31300M | -25.74600M | -4.31200M | -4.52700M | -2.21100M |
| Sale purchase of stock | 4.49M | 5.89M | 1.79M | 199.72M | 15.45M |
| Other cashflows from financing activities | 26.71M | -2.45100M | 7.78M | 2.32M | 29.81M |
| Change to netincome | -45.72200M | 33.55M | 10.54M | 3.78M | 1.38M |
| Capital expenditures | 25.13M | 12.44M | 11.52M | 3.82M | 1.98M |
| Change receivables | - | -25.74600M | -4.31200M | - | - |
| Cash flows other operating | - | -0.24900M | -0.08800M | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | 39.00M | -88.62200M | - | - |
| Change in working capital | -57.93100M | -16.51800M | -20.31400M | -3.49400M | -2.64900M |
| Stock based compensation | 44.89M | 27.26M | 10.35M | 3.65M | 1.30M |
| Other non cash items | 7.20M | 0.51M | 0.65M | 0.44M | 0.21M |
| Free cash flow | 92.61M | 2.60M | -82.70400M | -51.92400M | -43.44600M |
Sector: Healthcare Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| SWAV Shockwave Medical Inc |
- -% | - | 78.72 | 68.49 | 16.83 | 18.38 | 16.53 | 63.03 |
| ABT Abbott Laboratories |
-0.58 0.66% | 87.83 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| SYK Stryker Corporation |
-3.11 1.01% | 304.69 | 44.07 | 24.94 | 5.51 | 6.12 | 6.05 | 25.73 |
| MDT Medtronic PLC |
-0.07 0.09% | 79.27 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| BSX Boston Scientific Corp |
-0.96 2.12% | 44.33 | 31.49 | 17.24 | 4.41 | 3.65 | 4.88 | 19.19 |
Shockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system; and Reducer, a device to treat refractory angina. In addition, the company develops COSIRA-II trial; shockwave C2 Aero, a coronary IVL catheter; shockwave javelin coronary, a non-balloon-based catheter platform to treat of tight, difficult-to-cross coronary lesions; shockwave L6; shockwave E8 catheter, to target long peripheral artery lesions; shockwave javelin peripheral, a non-balloon-based catheter platform, to treat tight, difficult-to-cross peripheral lesions. Further, it offers shockwave carotid IVL, a purpose-built IVL System to treat calcified carotid artery lesions; and Shockwave Crescendo, a platform developed to treat calcified, stenotic heart valves. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.
5403 Betsy Ross Drive, Santa Clara, CA, United States, 95054
| Name | Title | Year Born |
|---|---|---|
| Mr. Douglas E. Godshall M.B.A. | Pres, CEO & Director | 1965 |
| Mr. Daniel Puckett MBA | CFO, Principal Financial Officer & Sec. | 1964 |
| Mr. Isaac Zacharias | Chief Commercial Officer | 1975 |
| Mr. Daniel Hawkins | Founder and Sr. Advisor | 1967 |
| Mr. John M. Adams | Co-Founder and Technical Advisor | 1947 |
| Mr. Mike Maszy | VP of Operations | NA |
| Ms. Trinh Phung | Chief Accounting Officer, Principal Accounting Officer & VP of Fin. | 1978 |
| Ms. Debbie Kaster | VP of Investor Relations | NA |
| Mr. Hajime Tada J.D. | Gen. Counsel & Sec. | NA |
| Mr. Rob Williamson Jr. | VP of Sales | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...